US 11,732,052 B2
Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine
Carole Bourquin, Belfaux (CH); Raffaella Castoldi, Munich (DE); Stefan Endres, Munich (DE); Christian Klein, Bonstetten (CH); Sebastian Kobold, Munich (DE); Gerhard Niederfellner, Oberhausen (DE); and Claudio Sustmann, Munich (DE)
Filed by Hoffmann-La Roche Inc., Nutley, NJ (US); and Ludwig-Maximilians-Universitat Munchen, Munich (DE)
Filed on Apr. 2, 2020, as Appl. No. 16/838,979.
Application 16/838,979 is a continuation of application No. 14/376,364, granted, now 10,633,451, previously published as PCT/EP2013/051351, filed on Jan. 24, 2013.
Claims priority of application No. 12153786 (EP), filed on Feb. 3, 2012.
Prior Publication US 2020/0317806 A1, Oct. 8, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/32 (2006.01)
CPC C07K 16/30 (2013.01) [A61K 39/001102 (2018.08); A61K 39/39558 (2013.01); C07K 16/2863 (2013.01); C07K 16/32 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/31 (2013.01); Y02P 20/582 (2015.11)] 19 Claims
 
1. A kit comprising
(A) a bispecific antibody molecule which comprises
(i) a first binding domain comprising a variable heavy chain (VH) and a variable light chain (VL) which binds an antigen on CD8+ T-cells that does not naturally occur in or on CD8+ T-cells, wherein the antigen is selected from the group consisting of cripto, a member of a non-T-cell cluster of differentiation (CD) family, EGFR, and TSH-R; and
(ii) a second binding domain comprising a VH and a VL which binds a tumor-specific antigen naturally occurring on the surface of a tumor cell, wherein the antigen is selected from the group consisting of EpCAM, HER-1, HER-2, HER-3, CD20, CD22, CD33, CD52, CA-12-5, HLA-DR, MUC-1 (mucin), A33-antigen, PSMA (prostate specific membrane antigen), Transferrin-receptor, Tenascin, and CA-IX; and
(B) a vector comprising a nucleic acid sequence encoding the antigen that does not naturally occur in or on CD8+ T-cells for transducing CD8+ T-cells obtained from a subject to be treated for a cancer, wherein cells of the cancer express the tumor-specific antigen naturally occurring on their surface; and
(C) instructions for use; wherein the bispecific antibody is to be administered to a subject to be treated for a cancer before, simultaneously with, or after administration of the transduced CD8+ T-cells comprising the antigen that does not naturally occur in or on CD8+ T-cells; wherein the CD8+ T-cells were obtained from the subject to be treated for a cancer; wherein cells of the cancer express the tumor-specific antigen naturally occurring on their surface.